What is it about?
Recent meta-analysis using aspirin trial data suggested that in primary cardiovascular disease (CVD) prevention body weight modified low-dose aspirin's effects on colorectal cancer (CRC) and major bleeding risk. We sought to investigate whether these effects are seen in patients with or without CVD in routine clinical practice by undertaking sub-analyses of data from two cohort studies with nested-case-control analyses.
Featured Image
Why is it important?
To evaluate if our study shows the same effect by body weight similar to the meta-analyses or not as this has implications in clinical practice for prescribing low-dose aspirin for cardiovascular prevention. Our study found that body weight did not modify aspirin’s protective effect against colorectal cancer. Body weight did not modify aspirin’s effect on upper gastrointestinal bleeding risk.
Perspectives
The results from the meta-analyses were hypothesis generating for this topic and apart from our study, further research and studies in different populations are needed to evaluate if this is a true effect or not
Pareen Vora
Bayer AG
Read the Original
This page is a summary of: The effect of low-dose aspirin on colorectal cancer prevention and gastrointestinal bleeding according to bodyweight and body mass index: Analysis of UK primary care data, International Journal of Cardiology, August 2019, Elsevier,
DOI: 10.1016/j.ijcard.2019.08.001.
You can read the full text:
Contributors
The following have contributed to this page
